Market News

FENC Stock Earnings: Fennec Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023

by Ron Finklestien

Published On: March 21, 2024 8:55 pm

Fennec Pharmaceuticals Q4 2023 Earnings Review

Fennec Pharmaceuticals Falls Short on EPS, Surpasses Revenue Expectations

FENC stock - Fennec Pharmaceuticals Q4 2023 Earnings

Source: iQoncept / Shutterstock

Fennec Pharmaceuticals (NASDAQ:FENC) has unveiled its performance for the fourth quarter of 2023.

Fennec Pharmaceuticals recorded earnings per share of -10 cents, failing to meet the analyst projection of -2 cents.
The company generated revenue amounting to $9.74 million, exceeding the anticipated $8.67 million by 12.28%.

InvestorPlace Earnings operates through TradeSmith data and automated monitoring of quarterly earnings. It summarizes critical insights such as earnings per share and revenue comparisons to analyst predictions. These reports are swiftly delivered to our readers for prompt updates. For corrections or issues, reach out to us at [email protected].

Article printed from InvestorPlace Media, https://investorplace.com/earning-results/2024/03/fenc-stock-earnings-fennec-pharmaceuticals-for-q4-of-2023/.